Jonathan Kaufman, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (218 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2005

Call 404-778-0519

Background

Jonathan L. Kaufman, MD, is Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in medical oncology, Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients at Emory University Hospital. As a network physician, he started practicing with Emory Healthcare in 2005. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant.

Dr. Kaufman earned his Medical Degree from the Medical College of Georgia in Augusta. He subsequently completed his Residency in Internal Medicine and his Fellowship in Hematology and Oncology at Emory University.

Titles & Roles

David Bankes Glass Multiple Myeloma Professorship

Emory University School of Medicine
Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Medical Director and Section Chief, Ambulatory Infusion Centers

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Hematology & Oncology, 2005
Emory University School of Medicine
Residency, Internal Medicine, 2001
Emory University School of Medicine
Internship, Internal Medicine, 2000
Emory University School of Medicine
Medical Education, MD, 1999
Medical College of Georgia

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2005

Professional Memberships

Dr. Kaufman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He holds professional memberships with American Society of Clinical Oncology, International Myeloma Society and American Society of Hematology.

Research

View Current Clinical Trials


P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma Phase I Conditions Multiple Myeloma Location Winship Cancer Institute
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis Phase III Conditions AL Amyloidosis Location Emory University Hospital Midtown, Winship Cancer Institute
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Phase III Conditions Multiple Myeloma Location Winship Cancer Institute
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis Phase I Conditions Light Chain (AL) Amyloidosis Location Winship Cancer Institute
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Phase Early Phase I Conditions Multiple Myeloma Location Winship Cancer Institute
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma Phase Expanded Access Conditions Multiple Myeloma Location Winship Cancer Institute
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma Phase I/II Conditions Relapsed/Refractory Multiple Myeloma Location Winship Cancer Institute
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma Phase I/II Conditions Multiple Myeloma, Plasma Cell Disorder Location Winship Cancer Institute
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma Phase I Conditions Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Location Winship Cancer Institute
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release Phase Expanded Access Conditions Multiple Myeloma Location Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma. Blood advances	SV Potdar, S Kapadia, MI Azeem, R Radzievski, K Lakhani, NS Joseph, JL Kaufman, CC Hofmeister, VA Gupta, S Lonial, AK Nooka, KM Dhodapkar, MV Dhodapkar	05/27/2025
BCL2 inhibition for multiple myeloma and AL amyloidosis. British journal of haematology	L Cani, VA Gupta, JL Kaufman	05/01/2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. Clinical lymphoma, myeloma & leukemia	P Rodriguez-Otero, PM Voorhees, M Boccadoro, J Laubach, H Einsele, DW Sborov, MA Dimopoulos, A Broijl, R Mina, A Spencer, F Schjesvold, R Silbermann, F Gay, LJ Costa, A Perrot, Y Liu, J Wang, A Sitthi-Amorn, R Carson, A Cortoos, SZ Usmani, PG Richardson, P Moreau, P Sonneveld, JL Kaufman	04/11/2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes. Clinical lymphoma, myeloma & leukemia	C Varga, M Robinson, V Gupta, CC Hofmeister, AK Nooka, JL Kaufman, MV Dhodapkar, S Lonial, S Borden, C Ferreri, B Paul, S Atrash, M Bhutani, PM Voorhees, NS Joseph	04/11/2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clinical lymphoma, myeloma & leukemia	SA Scott, DL Roberts, VA Gupta, NS Joseph, CC Hofmeister, MV Dhodapkar, S Lonial, AK Nooka, JL Kaufman	04/08/2025
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma. Blood	DT Vogl, S Atrash, SA Holstein, O Nadeem, D Benson, M Chaudry, N Biran, K Suryanarayan, C Li, Y Liu, S Collins, X Parot, JL Kaufman	02/27/2025
Solvitur ambulando. Blood	JL Kaufman	01/02/2025
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future oncology (London, England)	PM Voorhees, DW Sborov, J Laubach, JL Kaufman, B Reeves, C Rodriguez, R Silbermann, LJ Costa, LD Anderson, N Nathwani, N Shah, N Bumma, YA Efebera, SA Holstein, C Costello, A Jakubowiak, TM Wildes, RZ Orlowski, KH Shain, AJ Cowan, S Dinner, KS Gries, H Pei, A Cortoos, S Patel, TS Lin, SZ Usmani, PG Richardson	01/01/2025
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Investigational new drugs	MA Badawi, B Engelhardt, E Dobkowska, R Deng, JL Kaufman, R Menon, AH Salem	12/01/2024
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials. Cancer	JL Metts, JM Aye, JN Crane, S Oberoi, FM Balis, S Bhatia, K Bona, B Carleton, R Dasgupta, FS Dela Cruz, KA Greenzang, JL Kaufman, CM Linardic, SK Parsons, M Robertson-Tessi, ER Rudzinski, A Soragni, E Stewart, BJ Weigel, SL Wolden, AR Weiss, R Venkatramani, CM Heske	11/15/2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity. NPJ vaccines	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	10/27/2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nature cancer	S Richard, AM Lesokhin, B Paul, JL Kaufman, M Pianko, N Biran, R Vij, DB Doxie, MI Azeem, M Martillo, K Wozniak, HJ Cho, KM Dhodapkar, MV Dhodapkar	10/01/2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood cancer journal	NS Joseph, JL Kaufman, VA Gupta, CC Hofmeister, MV Dhodapkar, LH Boise, SM DiCamillo, D Roberts, AK Nooka, S Lonial	09/13/2024
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells. Nucleic acids research	M Cinar, L Martinez-Medina, PK Puvvula, A Arakelyan, BN Vardarajan, N Anthony, GP Nagaraju, D Park, L Feng, F Sheff, M Mosunjac, D Saxe, S Flygare, OB Alese, JL Kaufman, S Lonial, JM Sarmiento, IS Lossos, PM Vertino, JA Lopez, B El-Rayes, L Bernal-Mizrachi	07/22/2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood cancer journal	A Chari, JL Kaufman, J Laubach, DW Sborov, B Reeves, C Rodriguez, R Silbermann, LJ Costa, LD Anderson, N Nathwani, N Shah, N Bumma, SA Holstein, C Costello, A Jakubowiak, TM Wildes, RZ Orlowski, KH Shain, AJ Cowan, H Pei, A Cortoos, S Patel, TS Lin, PM Voorhees, SZ Usmani, PG Richardson	07/08/2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. American journal of hematology	R Silbermann, J Laubach, JL Kaufman, DW Sborov, B Reeves, C Rodriguez, A Chari, LJ Costa, LD Anderson, N Nathwani, N Shah, N Bumma, SA Holstein, C Costello, A Jakubowiak, RZ Orlowski, KH Shain, AJ Cowan, KS Gries, H Pei, A Cortoos, S Patel, TS Lin, PM Voorhees, SZ Usmani, PG Richardson	07/01/2024
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA. The Lancet. Haematology	MK Khan, TH Nasti, JY Qian, TJ Kleber, JM Switchenko, JL Kaufman, AJ Nooka, MV Dhodapkar, ZS Buchwald, D Obiekwe, S Lonial, R Ahmed	07/01/2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British journal of haematology	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, TM Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, TS Lin, PM Voorhees, SZ Usmani, PG Richardson	06/01/2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The Lancet. Oncology	P Rodriguez-Otero, S Usmani, AD Cohen, NWCJ van de Donk, X Leleu, J Gállego Pérez-Larraya, S Manier, AK Nooka, MV Mateos, H Einsele, M Minnema, M Cavo, BA Derman, N Puig, F Gay, PJ Ho, WJ Chng, E Kastritis, G Gahrton, K Weisel, C Nagarajan, F Schjesvold, J Mikhael, L Costa, NS Raje, E Zamagni, R Hájek, N Weinhold, K Yong, JC Ye, S Sidhana, G Merlini, T Martin, Y Lin, A Chari, R Popat, JL Kaufman	05/01/2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood cancer journal	NS Callander, R Silbermann, JL Kaufman, KN Godby, J Laubach, TM Schmidt, DW Sborov, E Medvedova, B Reeves, B Dhakal, C Rodriguez, S Chhabra, A Chari, S Bal, LD Anderson, BR Dholaria, N Nathwani, P Hari, N Shah, N Bumma, SA Holstein, C Costello, A Jakubowiak, TM Wildes, RZ Orlowski, KH Shain, AJ Cowan, H Pei, A Cortoos, S Patel, TS Lin, S Giri, LJ Costa, SZ Usmani, PG Richardson, PM Voorhees	04/22/2024
Glücksklee, the Quad, and High-Risk Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, JL Kaufman, S Lonial	01/01/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	12/20/2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The oncologist	CS Lalonde, JM Switchenko, M Behera, MA Bilen, TK Owonikoko, JL Kaufman, AK Nooka, CM Lewis, E Hitron, H Collins, EC Judson, OB Alese, R Donald Harvey, JW Carlisle	12/11/2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. The Lancet. Haematology	PM Voorhees, DW Sborov, J Laubach, JL Kaufman, B Reeves, C Rodriguez, A Chari, R Silbermann, LJ Costa, LD Anderson, N Nathwani, N Shah, N Bumma, YA Efebera, SA Holstein, C Costello, A Jakubowiak, TM Wildes, RZ Orlowski, KH Shain, AJ Cowan, S Dinner, H Pei, A Cortoos, S Patel, TS Lin, SZ Usmani, PG Richardson	10/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. Research square	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	09/21/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	09/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. bioRxiv : the preprint server for biology	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	08/22/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	08/01/2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia	MS Raab, YC Cohen, F Schjesvold, K Aardalen, A Oka, A Spencer, M Wermke, AD Souza, JL Kaufman, AM Cafro, EM Ocio, N Doki, K Henson, G Trabucco, A Carrion, FC Bender, PE Juif, A Fessehatsion, L Fan, JP Stonehouse, JW Blankenship, B Granda, S De Vita, H Lu	06/01/2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. Journal for immunotherapy of cancer	S Raghunandan, M Pauly, WG Blum, M Qayed, MV Dhodapkar, M Elkhalifa, B Watkins, M Schoettler, E Horwitz, S Parikh, S Chandrakasan, K Leung, E Bryson, L Deeb, JL Kaufman, D Worthington-White, A Alazraki, JM Schecter, D Madduri, CC Jackson, E Zudaire, A Taraseviciute-Morris, A Babich, T Nesheiwat, M Vogel, N Lendvai, L Pacaud, KM Williams	05/01/2023
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood cancer discovery	MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, RJ Manalo, A Moreno, JM Switchenko, S Cheedarla, DB Doxie, R Radzievski, ML Ellis, KE Manning, B Wali, RM Valanparambil, KT Maples, E Baymon, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, JD Roback, A Sette, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar, KM Dhodapkar	03/01/2023
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplantation and cellular therapy	S Chhabra, N Callander, NL Watts, LJ Costa, B Thapa, JL Kaufman, J Laubach, DW Sborov, B Reeves, C Rodriguez, A Chari, R Silbermann, LD Anderson, S Bal, B Dhakal, N Nathwani, N Shah, E Medvedova, N Bumma, SA Holstein, C Costello, A Jakubowiak, TM Wildes, T Schmidt, RZ Orlowski, KH Shain, AJ Cowan, B Dholaria, RF Cornell, JH Jerkins, H Pei, A Cortoos, S Patel, TS Lin, SZ Usmani, PG Richardson, PM Voorhees	03/01/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	02/20/2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future oncology (London, England)	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, T Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, TS Lin, PG Richardson, P Voorhees	12/01/2022
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia	M Slade, TG Martin, N Nathwani, MA Fiala, MP Rettig, F Gao, A Deol, FK Buadi, JL Kaufman, CC Hofmeister, TK Gregory, J Berdeja, A Chari, A Rosko, R Vij	12/01/2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. British journal of haematology	DW Sborov, M Baljevic, B Reeves, J Laubach, YA Efebera, C Rodriguez, LJ Costa, A Chari, R Silbermann, SA Holstein, LD Anderson, JL Kaufman, N Shah, H Pei, S Patel, A Cortoos, JB Bartlett, J Vermeulen, TS Lin, PM Voorhees, PG Richardson	11/01/2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, R Valanparambil, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, M Azeem, J Manalo, JM Switchenko, A Chang, SL Linderman, JD Roback, KM Dhodapkar, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar	09/10/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	08/04/2022
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. The New England journal of medicine	PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, E Medvedova, PL McCarthy, EN Libby, PM Voorhees, RZ Orlowski, LD Anderson, JA Zonder, CP Milner, C Gasparetto, ME Agha, AM Khan, DD Hurd, K Gowin, RT Kamble, S Jagannath, N Nathwani, M Alsina, RF Cornell, H Hashmi, EL Campagnaro, AC Andreescu, T Gentile, M Liedtke, KN Godby, AD Cohen, TH Openshaw, MC Pasquini, SA Giralt, JL Kaufman, AJ Yee, E Scott, P Torka, A Foley, M Fulciniti, K Hebert, MK Samur, K Masone, ME Maglio, AA Zeytoonjian, O Nadeem, RL Schlossman, JP Laubach, C Paba-Prada, IM Ghobrial, A Perrot, P Moreau, H Avet-Loiseau, M Attal, KC Anderson, NC Munshi	07/14/2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Haematology	MA Dimopoulos, PG Richardson, NJ Bahlis, S Grosicki, M Cavo, M Beksaç, W Legieć, AM Liberati, H Goldschmidt, A Belch, H Magen, A Larocca, JP Laubach, MT Petrucci, D Reece, D White, MV Mateos, I Špička, M Lazaroiu, J Berdeja, JL Kaufman, YM Jou, A Ganetsky, M Popa McKiver, S Lonial, K Weisel	06/01/2022
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood cancer journal	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, T Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, JB Bartlett, J Vermeulen, TS Lin, PG Richardson, P Voorhees	04/13/2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy	A Sivakumar, EB Bryson, KH Hall, KT Maples, S Goyal, NS Joseph, CC Hofmeister, JL Kaufman, S Lonial, AK Nooka, RD Harvey	03/01/2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet. Haematology	NS Raje, E Anaissie, SK Kumar, S Lonial, T Martin, MA Gertz, A Krishnan, P Hari, H Ludwig, E O'Donnell, A Yee, JL Kaufman, AD Cohen, L Garderet, AF Wechalekar, E Terpos, N Khatry, R Niesvizky, Q Yi, DE Joshua, T Saikia, N Leung, M Engelhardt, M Mothy, A Branagan, A Chari, AJ Reiman, B Lipe, J Richter, SV Rajkumar, JS Miguel, KC Anderson, EA Stadtmauer, RH Prabhala, PL McCarthy, NC Munshi	02/01/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	02/01/2022
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer medicine	D Pan, JL Kaufman, M Htut, M Agrawal, A Mazumder, RF Cornell, JA Zonder, JW Fay, MR Modiano, EL Moshier, SA Rush, BJ Tunquist, A Chari	01/01/2022
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient preference and adherence	D Auclair, C Mansfield, MA Fiala, A Chari, CE Cole, JL Kaufman, GJ Orloff, DS Siegel, JA Zonder, B Mange, J Yesil, M Dalal, JR Mikhael	01/01/2022
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NJ Bahlis, R Baz, SJ Harrison, H Quach, SJ Ho, AJ Vangsted, T Plesner, P Moreau, SD Gibbs, S Coppola, X Yang, A Al Masud, JA Ross, O Bueno, JL Kaufman	11/10/2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	11/01/2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood advances	LJ Costa, FE Davies, GP Monohan, T Kovacsovics, N Burwick, A Jakubowiak, JL Kaufman, WJ Hong, M Dail, AH Salem, X Yang, AA Masud, W Munasinghe, JA Ross, OF Bueno, SK Kumar, EA Stadtmauer	10/12/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	07/01/2021
Defining the Value of Interventional Radiology to Healthcare Stakeholders: Proceedings from a Society of Interventional Radiology Research Consensus Panel. Journal of vascular and interventional radiology : JVIR	CM Hawkins, R Duszak, DR Hughes, R Liu, AS Resnick, DA Kooby, JC Durack, JA Kaufman, F Dubeck, MB Canada, KL Krol, SB White	07/01/2021
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica	J San-Miguel, SZ Usmani, MV Mateos, NWCJ van de Donk, JL Kaufman, P Moreau, A Oriol, T Plesner, L Benboubker, K Liu, P Hellemans, T Masterson, PL Clemens, M Luo, A Farnsworth, H Nahi, A Chari	06/01/2021
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American journal of hematology	JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, T Facon, LH Boise, Y Jiang, X Yang, F Dunbar, D Vishwamitra, S Unger, T Macartney, J Pesko, Y Yu, AH Salem, JA Ross, WJ Hong, PC Maciag, JM Pauff, S Kumar	04/01/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	03/01/2021
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. Blood and lymphatic cancer : targets and therapy	VA Gupta, J Ackley, JL Kaufman, LH Boise	01/01/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	12/14/2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	JL Kaufman, R Mina, JJ Shah, JP Laubach, AK Nooka, C Lewis, C Gleason, C Sharp, RD Harvey, LT Heffner, P Richardson, S Lonial, RZ Orlowski	12/01/2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia	J Mikhael, J Richter, R Vij, C Cole, J Zonder, JL Kaufman, W Bensinger, M Dimopoulos, N Lendvai, P Hari, EM Ocio, C Gasparetto, S Kumar, C Oprea, M Chiron, C Brillac, E Charpentier, J San-Miguel, T Martin	12/01/2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood cancer journal	JL Kaufman, MA Dimopoulos, D White, L Benboubker, G Cook, M Leiba, J Morton, P Joy Ho, K Kim, N Takezako, P Moreau, HJ Sutherland, H Magen, S Iida, JS Kim, H Miles Prince, T Cochrane, A Oriol, NJ Bahlis, A Chari, L O'Rourke, S Trivedi, T Casneuf, M Krevvata, J Ukropec, R Kobos, H Avet-Loiseau, SZ Usmani, J San-Miguel	11/03/2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood	PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, C Rodriguez, A Chari, R Silbermann, LJ Costa, LD Anderson, N Nathwani, N Shah, YA Efebera, SA Holstein, C Costello, A Jakubowiak, TM Wildes, RZ Orlowski, KH Shain, AJ Cowan, S Murphy, Y Lutska, H Pei, J Ukropec, J Vermeulen, C de Boer, D Hoehn, TS Lin, PG Richardson	08/20/2020
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood	G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, N Bumma, JL Kaufman, E Medvedova, T Kovacsovics, M Rosenzweig, V Sanchorawala, X Qin, SY Vasey, BM Weiss, J Vermeulen, G Merlini, RL Comenzo	07/02/2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia	NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, PJ Ho, K Kim, N Takezako, P Moreau, JL Kaufman, M Krevvata, C Chiu, X Qin, L Okonkwo, S Trivedi, J Ukropec, M Qi, J San-Miguel	07/01/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	06/10/2020
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood cancer journal	R Mina, NS Joseph, F Gay, E Kastritis, MT Petrucci, JL Kaufman, V Montefusco, M Gavriatopoulou, F Patriarca, P Omedé, LH Boise, M Roussou, N Giuliani, S Oliva, M Offidani, A Belotti, DL Jaye, L De Paoli, E Terpos, S Lonial, M Boccadoro, AK Nooka, MA Dimopoulos	04/14/2020
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, S Jacobus, R Fonseca, M Weiss, S Kumar, RZ Orlowski, JL Kaufman, AM Yacoub, FK Buadi, T O'Brien, JV Matous, DM Anderson, RV Emmons, A Mahindra, LI Wagner, MV Dhodapkar, SV Rajkumar	04/10/2020
Roundtable: How I treat a newly diagnosed patient with high-risk myeloma. Hematology. American Society of Hematology. Education Program	JL Kaufman	12/06/2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	11/25/2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer	AK Nooka, NS Joseph, JL Kaufman, LT Heffner, VA Gupta, C Gleason, LH Boise, S Lonial	09/01/2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood	SZ Usmani, H Nahi, MV Mateos, NWCJ van de Donk, A Chari, JL Kaufman, P Moreau, A Oriol, T Plesner, L Benboubker, P Hellemans, T Masterson, PL Clemens, M Luo, K Liu, J San-Miguel	08/22/2019
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research	IM Ghobrial, R Vij, D Siegel, A Badros, J Kaufman, N Raje, A Jakubowiak, MR Savona, M Obreja, JG Berdeja	08/15/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	07/15/2019
Registering a CD38 antibody upfront for multiple myeloma. Lancet (London, England)	CC Hofmeister, A Nooka, JL Kaufman, S Lonial	07/06/2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. Cancer	RD Harvey, C Zhang, S Lonial, JL Kaufman, Z Chen	07/01/2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia	SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, AK Stewart, P Hari, V Roy, R Vescio, JL Kaufman, D Berg, E Liao, SV Rajkumar, PG Richardson	07/01/2019
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical lymphoma, myeloma & leukemia	I Ghobrial, CH Cruz, A Garfall, N Shah, N Munshi, J Kaufman, LH Boise, G Morgan, VA Adalsteinsson, S Manier, R Pillai, F Malavasi, S Lonial	06/01/2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia	SM Matulis, VA Gupta, P Neri, NJ Bahlis, P Maciag, JD Leverson, LT Heffner, S Lonial, AK Nooka, JL Kaufman, LH Boise	05/01/2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight	JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, N Neparidze, TL Parker, N Bar, JL Kaufman, CC Hofmeister, LH Boise, S Lonial, ML Kemp, KM Dhodapkar, MV Dhodapkar	04/23/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	04/23/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	02/01/2019
Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer	NS Joseph, JL Kaufman, LH Boise, K Valla, DK Almaula, CO Obidike, AA Langston, EK Waller, HJ Khoury, CR Flowers, M Graiser, LT Heffner, S Lonial, AK Nooka	01/15/2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood cancer journal	JL Kaufman, R Mina, AJ Jakubowiak, TL Zimmerman, JJ Wolf, C Lewis, C Gleason, C Sharp, T Martin, LT Heffner, AK Nooka, RD Harvey, S Lonial	01/04/2019
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica	MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, M Leiba, J Morton, PJ Ho, K Kim, N Takezako, P Moreau, JL Kaufman, HJ Sutherland, M Lalancette, H Magen, S Iida, JS Kim, HM Prince, T Cochrane, A Oriol, NJ Bahlis, A Chari, L O'Rourke, K Wu, JM Schecter, T Casneuf, C Chiu, D Soong, AK Sasser, NZ Khokhar, H Avet-Loiseau, SZ Usmani	12/01/2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA oncology	AK Nooka, ML Wang, AJ Yee, JL Kaufman, J Bae, D Peterkin, PG Richardson, NS Raje	12/01/2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer	S Chehab, C Zhang, EH Panjic, Z Chen, JL Kaufman, S Lonial, A Nooka, RD Harvey	11/15/2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of oncology practice	A Chang, TH Nasti, MK Khan, S Parashar, JL Kaufman, LH Boise, S Lonial, R Ahmed, AK Nooka	09/01/2018
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	IN Micallef, PJ Stiff, AP Nademanee, RT Maziarz, ME Horwitz, EA Stadtmauer, JL Kaufman, JM McCarty, R Vargo, PD Cheverton, M Struijs, B Bolwell, JF DiPersio	06/01/2018
Novel Approaches for the Management of AL Amyloidosis. Current hematologic malignancy reports	NS Joseph, JL Kaufman	06/01/2018
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clinical lymphoma, myeloma & leukemia	MA Dimopoulos, JL Kaufman, D White, G Cook, M Rizzo, Y Xu, K Fahrbach, M Gaudig, M Slavcev, L Dearden, A Lam	03/01/2018
14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia	Y Gu, K Xu, C Torre, M Samur, BG Barwick, M Rupji, J Arora, P Neri, J Kaufman, A Nooka, L Bernal-Mizrachi, P Vertino, SY Sun, J Chen, N Munshi, H Fu, J Kowalski, LH Boise, S Lonial	03/01/2018
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer	JJ Shah, JL Kaufman, JA Zonder, AD Cohen, WI Bensinger, BW Hilder, SA Rush, DH Walker, BJ Tunquist, KS Litwiler, M Ptaszynski, RZ Orlowski, S Lonial	12/01/2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood	S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, L Benboubker, T Facon, M Amiot, P Moreau, EA Punnoose, S Alzate, M Dunbar, T Xu, SK Agarwal, SH Enschede, JD Leverson, JA Ross, PC Maciag, M Verdugo, C Touzeau	11/30/2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood	A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, JJ Ifthikharuddin, BM Weiss, A Krishnan, S Lentzsch, R Comenzo, J Wang, K Nottage, C Chiu, NZ Khokhar, T Ahmadi, S Lonial	08/24/2017
High-risk Multiple Myeloma: Definition and Management. Clinical lymphoma, myeloma & leukemia	NS Joseph, S Gentili, JL Kaufman, S Lonial, AK Nooka	07/01/2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood	VA Gupta, SM Matulis, JE Conage-Pough, AK Nooka, JL Kaufman, S Lonial, LH Boise	04/06/2017
New Treatment Strategies Making an Impact in Multiple Myeloma. Journal of the advanced practitioner in oncology	C Gleason, J Kaufman	04/01/2017
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone marrow transplantation	Z DeFilipp, CB Rosand, DA Goldstein, VA Master, BC Carthon, WB Harris, O Kucuk, Z Al-Kadhimi, JB Cohen, CR Flowers, MJ Lechowicz, AK Nooka, JL Kaufman, AA Langston, Z Chen, J Arora, EK Waller	01/01/2017
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer	A Chari, M Htut, JA Zonder, JW Fay, AJ Jakubowiak, JB Levy, K Lau, SM Burt, BJ Tunquist, BW Hilder, SA Rush, DH Walker, M Ptaszynski, JL Kaufman	11/15/2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert opinion on biological therapy	S Lonial, J Kaufman, D Reece, MV Mateos, J Laubach, P Richardson	10/01/2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer biology & therapy	KG Ponder, SM Matulis, S Hitosugi, VA Gupta, C Sharp, F Burrows, AK Nooka, JL Kaufman, S Lonial, LH Boise	07/02/2016
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood	PG Richardson, TM Zimmerman, CC Hofmeister, M Talpaz, AA Chanan-Khan, JL Kaufman, JP Laubach, D Chauhan, AJ Jakubowiak, S Reich, M Trikha, KC Anderson	06/02/2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	DS Siegel, M Dimopoulos, S Jagannath, H Goldschmidt, S Durrant, JL Kaufman, X Leleu, A Nagler, F Offner, T Graef, JE Eid, J Houp, C Gause, S Vuocolo, KC Anderson	06/01/2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget	J Deng, D Park, M Wang, A Nooka, Q Deng, S Matulis, J Kaufman, S Lonial, LH Boise, J Galipeau, X Deng	05/10/2016
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia	SM Matulis, VA Gupta, AK Nooka, HV Hollen, JL Kaufman, S Lonial, LH Boise	05/01/2016
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. Clinical lymphoma, myeloma & leukemia	J Berdeja, S Jagannath, J Zonder, A Badros, JL Kaufman, R Manges, M Gupta, A Tendolkar, M Lynch, E Bleickardt, P Paliwal, R Vij	03/01/2016
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood	JJ Shah, EA Stadtmauer, R Abonour, AD Cohen, WI Bensinger, C Gasparetto, JL Kaufman, S Lentzsch, DT Vogl, CL Gomes, N Pascucci, DD Smith, RZ Orlowski, BG Durie	11/12/2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. British journal of haematology	JB Cohen, JM Switchenko, JL Koff, R Sinha, JL Kaufman, HJ Khoury, N Bumpers, A Colbert, A Hutchison-Rzepka, LJ Nastoupil, LT Heffner, AA Langston, MJ Lechowicz, S Lonial, CR Flowers	11/01/2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Transfusion	N Jagirdar, RD Harvey, A Nooka, C Flowers, J Kaufman, S Lonial, MJ Lechowicz, A Langston, C Lipscomb, C Gaylor, EK Waller	10/01/2015
How I treat high-risk myeloma. Blood	S Lonial, LH Boise, J Kaufman	09/24/2015
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. Cancer	MS Barbee, A Nooka, JL Kaufman, S Kim, Z Chen, LT Heffner, S Lonial, RD Harvey	03/15/2015
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leukemia & lymphoma	LJ Nastoupil, PJ Shenoy, A Ambinder, JL Koff, AK Nooka, EK Waller, A Langston, M Seward, JL Kaufman, L Bernal-Mizrachi, N King, MJ Lechowicz, S Lonial, R Sinha, CR Flowers	02/01/2015
Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema. Clinical lymphoma, myeloma & leukemia	SR Shams, DA Goldstein, JL Kaufman, J MacKelfresh, CR Flowers, AA Langston	12/01/2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. The Lancet. Oncology	SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, AK Stewart, P Hari, V Roy, R Vescio, JL Kaufman, D Berg, E Liao, A Di Bacco, J Estevam, N Gupta, AM Hui, V Rajkumar, PG Richardson	12/01/2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. The Lancet. Oncology	JF San-Miguel, VT Hungria, SS Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, A Günther, TN Nakorn, N Siritanaratkul, P Corradini, S Chuncharunee, JJ Lee, RL Schlossman, T Shelekhova, K Yong, D Tan, T Numbenjapon, JD Cavenagh, J Hou, R LeBlanc, H Nahi, L Qiu, H Salwender, S Pulini, P Moreau, K Warzocha, D White, J Bladé, W Chen, J de la Rubia, P Gimsing, S Lonial, JL Kaufman, EM Ocio, L Veskovski, SK Sohn, MC Wang, JH Lee, H Einsele, M Sopala, C Corrado, BR Bengoudifa, F Binlich, PG Richardson	10/01/2014
The Tao of myeloma. Blood	LH Boise, JL Kaufman, NJ Bahlis, S Lonial, KP Lee	09/18/2014
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	AK Nooka, HR Johnson, JL Kaufman, CR Flowers, A Langston, C Steuer, M Graiser, Z Ali, NN Shah, S Rangaraju, D Nickleach, J Gao, S Lonial, EK Waller	06/01/2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood	Y Gu, JL Kaufman, L Bernal, C Torre, SM Matulis, RD Harvey, J Chen, SY Sun, LH Boise, S Lonial	05/22/2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. Clinical lymphoma, myeloma & leukemia	AK Nooka, RD Harvey, A Langston, H Collins, S Lonial, JL Kaufman	04/01/2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood	PG Richardson, W Xie, S Jagannath, A Jakubowiak, S Lonial, NS Raje, M Alsina, IM Ghobrial, RL Schlossman, NC Munshi, A Mazumder, DH Vesole, JL Kaufman, K Colson, M McKenney, LE Lunde, J Feather, ME Maglio, D Warren, D Francis, T Hideshima, R Knight, DL Esseltine, CS Mitsiades, E Weller, KC Anderson	03/06/2014
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia	AK Nooka, JL Kaufman, S Muppidi, A Langston, LT Heffner, C Gleason, D Casbourne, D Saxe, LH Boise, S Lonial	03/01/2014
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone marrow transplantation	AA Langston, JM Prichard, S Muppidi, A Nooka, MJ Lechowicz, S Lonial, R Sinha, M Graiser, JL Kaufman, HJ Khoury, CR Flowers, EK Waller	02/01/2014
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer	AK Nooka, JL Kaufman, M Behera, A Langston, EK Waller, CR Flowers, C Gleason, LH Boise, S Lonial	12/01/2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia	R Sinha, PJ Shenoy, N King, MJ Lechowicz, K Bumpers, D Hutcherson, M Arellano, A Langston, J Kaufman, LT Heffner, EK Waller, A Nooka, CR Flowers, S Lonial	12/01/2013
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert opinion on biological therapy	S Lonial, J Kaufman, J Laubach, P Richardson	12/01/2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British journal of haematology	JL Kaufman, R Niesvizky, EA Stadtmauer, A Chanan-Khan, D Siegel, H Horne, WA Wegener, DM Goldenberg	11/01/2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	RD Harvey, JL Kaufman, HR Johnson, A Nooka, L Vaughn, CR Flowers, HJ Khoury, MJ Lechowicz, AA Langston, S Lonial, EK Waller	09/01/2013
Non-secretory myeloma: a clinician's guide. Oncology (Williston Park, N.Y.)	S Lonial, JL Kaufman	09/01/2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. The Annals of pharmacotherapy	MS Barbee, RD Harvey, S Lonial, JL Kaufman, NM Wilson, T McKibbin, DA Hutcherson, M Surati, K Valla, KS Shah	09/01/2013
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clinical lymphoma, myeloma & leukemia	JL Kaufman, C Fabre, S Lonial, PG Richardson	08/01/2013
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report. Clinical lymphoma, myeloma & leukemia	N Wilson, M Surati, BF Walker, JL Kaufman, RD Harvey	04/01/2013
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	S Lonial, M Akhtari, J Kaufman, C Torre, MJ Lechowicz, C Flowers, R Sinha, HJ Khoury, AA Langston, EK Waller	03/01/2013
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion	JL Kaufman, CR Flowers, KD Rados, GB Calandra, JM Vose, LB Hewes, S Lonial, AA Langston, HJ Khoury, MJ Lechowicz, EK Waller	01/01/2013
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. British journal of haematology	D Muringampurath-John, DL Jaye, CR Flowers, D Saxe, Z Chen, MJ Lechowicz, DD Weisenburger, M Bast, ML Arellano, L Bernal-Mizrachi, LT Heffner, M McLemore, JL Kaufman, EF Winton, S Lonial, JO Armitage, HJ Khoury	09/01/2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer	R Sinha, JL Kaufman, HJ Khoury, N King, PJ Shenoy, C Lewis, K Bumpers, A Hutchison-Rzepka, M Tighiouart, LT Heffner, MJ Lechowicz, S Lonial, CR Flowers	07/15/2012
The era of combination therapy in myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, JL Kaufman	07/10/2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood	R Vij, M Wang, JL Kaufman, S Lonial, AJ Jakubowiak, AK Stewart, V Kukreti, S Jagannath, KT McDonagh, M Alsina, NJ Bahlis, FJ Reu, NY Gabrail, A Belch, JV Matous, P Lee, P Rosen, M Sebag, DH Vesole, LA Kunkel, SM Wear, AF Wong, RZ Orlowski, DS Siegel	06/14/2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, R Vij, JL Harousseau, T Facon, P Moreau, A Mazumder, JL Kaufman, X Leleu, LC Tsao, C Westland, AK Singhal, S Jagannath	06/01/2012
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukemia & lymphoma	D Muringampurath-John, CR Flowers, M Toscano, C Zhengjia, JL Kaufman, M Arellano, L Bernal-Mizrachi, LT Heffner, MJ Lechowicz, M McLemore, E Winton, DL Jaye, S Lonial, HJ Khoury	04/01/2012
Optimizing stem cell collection through CXCR4 antagonists. Frontiers in bioscience (Scholar edition)	H Mahaseth, J Kaufman	01/01/2012
Toxicities of mobilized stem cell infusion. Methods in molecular biology (Clifton, N.J.)	JL Kaufman	01/01/2012
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion	J Li, E Hamilton, L Vaughn, M Graiser, H Renfroe, MJ Lechowicz, A Langston, JM Prichard, D Anderson, C Gleason, S Lonial, CR Flowers, JL Kaufman, EK Waller	10/01/2011
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood	AA Morales, M Kurtoglu, SM Matulis, J Liu, D Siefker, DM Gutman, JL Kaufman, KP Lee, S Lonial, LH Boise	08/04/2011
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. Transfusion	H Renfroe, M Arnold, L Vaughn, RD Harvey, E Hamilton, S Lonial, HJ Khoury, JL Kaufman, MJ Lechowicz, CR Flowers, EK Waller	08/01/2011
Putting the E (evidence) in a new Era for myeloma. Leukemia & lymphoma	JL Kaufman, S Lonial	03/01/2011
Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia	CR Giver, DL Jaye, EK Waller, JL Kaufman, S Lonial	02/01/2011
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood	E David, JL Kaufman, CR Flowers, K Schafer-Hales, C Torre, J Chen, AI Marcus, SY Sun, LH Boise, S Lonial	12/09/2010
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion	M Akhtari, CR Giver, Z Ali, CR Flowers, CL Gleason, CD Hillyer, J Kaufman, HJ Khoury, AA Langston, MJ Lechowicz, S Lonial, HM Renfroe, JD Roback, M Tighiouart, L Vaughn, EK Waller	11/01/2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clinical cancer research : an official journal of the American Association for Cancer Research	S Lonial, J Kaufman, M Tighiouart, A Nooka, AA Langston, LT Heffner, C Torre, S McMillan, H Renfroe, RD Harvey, MJ Lechowicz, HJ Khoury, CR Flowers, EK Waller	10/15/2010
Melphalan or no melphalan: that is the question. Oncology (Williston Park, N.Y.)	J Kaufman, S Lonial	10/01/2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood	PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, NS Raje, DE Avigan, W Xie, IM Ghobrial, RL Schlossman, A Mazumder, NC Munshi, DH Vesole, R Joyce, JL Kaufman, D Doss, DL Warren, LE Lunde, S Kaster, C Delaney, T Hideshima, CS Mitsiades, R Knight, DL Esseltine, KC Anderson	08/05/2010
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer	JL Kaufman, A Nooka, M Vrana, C Gleason, LT Heffner, S Lonial	07/01/2010
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science signaling	T Hitosugi, S Kang, MG Vander Heiden, TW Chung, S Elf, K Lythgoe, S Dong, S Lonial, X Wang, GZ Chen, J Xie, TL Gu, RD Polakiewicz, JL Roesel, TJ Boggon, FR Khuri, DG Gilliland, LC Cantley, J Kaufman, J Chen	11/17/2009
Treatment of multiple myeloma: whence truth over belief? Oncology (Williston Park, N.Y.)	J Kaufman, S Lonial	04/30/2009
Treatment of relapsed and refractory myeloma. Current hematologic malignancy reports	J Kaufman, C Gleason, S Lonial	04/01/2009
The importance of complete response in outcomes in myeloma. Cancer journal (Sudbury, Mass.)	A Nooka, J Kaufman, S Lonial	01/01/2009
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone marrow transplantation	S Murali, E Winton, EK Waller, LT Heffner, S Lonial, C Flowers, J Kaufman, M Arellano, MJ Lechowicz, KP Mann, HJ Khoury, AA Langston	10/01/2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clinical cancer research : an official journal of the American Association for Cancer Research	E David, R Sinha, J Chen, SY Sun, JL Kaufman, S Lonial	08/15/2008
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clinical lymphoma & myeloma	SP Gladney, S Lonial, JL Kaufman	02/01/2008
Maintenance therapy in lymphoma. Clinical lymphoma & myeloma	R Mihelic, J Kaufman, S Lonial, C Flowers	09/01/2007
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion	ML Hicks, S Lonial, A Langston, C Flowers, JD Roback, KJ Smith, S Mossavi Sai, D Teagarden, ES Hamilton, EK Waller, J Kaufman	04/01/2007
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood	AA Chanan-Khan, JL Kaufman, J Mehta, PG Richardson, KC Miller, S Lonial, NC Munshi, R Schlossman, J Tariman, S Singhal	03/15/2007
Proteasome inhibition: novel therapy for multiple myeloma. Onkologie	JL Kaufman, S Lonial	04/01/2006
Novel treatment approaches for patients with multiple myeloma. Clinical lymphoma & myeloma	R Sinha, JL Kaufman, S Lonial	01/01/2006
Multiple myeloma: the role of transplant and novel treatment strategies. Seminars in oncology	J Kaufman, S Lonial	04/01/2004

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	04/18/2025	Dr. Kaufman is always great!!
One star One star One star One star One star	04/18/2025	From the moment I walked into the office, I felt welcomed, heard, and truly cared for. Dr Kaufman and his medical team are not only knowledgeble and professional but also kind, attentive, and compassionate. He took the tome to listen to all of my concerns , explained everything to me and my eife, and answered all of our questions. I would highly recomment Dr. Kaufman based on my experience.
One star One star One star One star One star	04/15/2025	Questions and answers were professionally Thoroughly explained.
One star One star One star One star One star	03/28/2025	Excellent experience
One star One star One star One star One star	03/28/2025	Dr Kaufman is clearly an expert in stem cell treatments and was very thorough in words I could understand about the process, what to expect, and patiently answered all my questions about my disease, treatment options and risks
One star One star One star One star One star	03/23/2025	Always great experience
One star One star One star One star One star	03/13/2025	Dr Kaufman listened to all of our questions and concerns.
One star One star One star One star One star	03/02/2025	We cannot say enough wonderful things about Dr. Kaufman and his team. Highly recommend!
One star One star One star One star One star	01/31/2025	Good communications
One star One star One star One star One star	01/31/2025	Dr Kaufman was very direct
One star One star One star One star One star	01/30/2025	Always caring, concerned, and professional
One star One star One star One star One star	01/24/2025	Dr Kaufman's explanation regarding my biopsy and future treatment was very complete and encouraging. He made a change in my medication and explained the need in detail.
One star One star One star One star One star	01/09/2025	Dr. Kaufman was very kind, caring and professional and took time to explain everything to me And helped put me at ease
One star One star One star One star One star	01/01/2025	Dr. Kaufman is an outstanding doctor. He is thorough, insightful, kind and positive.
One star One star One star One star One star	01/01/2025	Dr. Kaufmann is the ultimate Multiple Myeloma Specialist.
One star One star One star One star One star	12/19/2024	Dr Kaufman is very caring and very thorough.
One star One star One star One star One star	12/14/2024	Dr. Kaufman takes the time to fully explain and make sure that I understand. He also always answers our questions and spends the time needed with us.
One star One star One star One star One star	12/11/2024	Dr. Kaufman has treated me now for over five years for my multiple myeloma. He is an exceptional physician and caregiver.I have felt so fortunate to be in his care.I am a physician myself here at Emory and as a result know a lot about medical care. Having said that I can say with the upmost confidence that Dr. Kauffman is one of the best physicians I have ever come to know and I am incredibly grateful for his outstanding care!
One star One star One star One star One star	12/05/2024	Very good
One star One star One star One star One star	11/29/2024	Dr Kaufman seems in the moment and focused whenever we interact.
One star One star One star One star One star	11/26/2024	Very concise instructions and comments regarding treatment.
One star One star One star One star One star	11/16/2024	The provider possessed all the qualities I told by the person referring him. He was very informative, thoughtful, a great listener, inclusive of me and spouse discussion and concerns. It was great to have Dr Jonathan Kaufman and Latonja as a team.
One star One star One star One star One star	11/15/2024	He always greet you with a smile. Always giving you a sure that everything is going to be alright under his watch.
One star One star One star One star One star	11/08/2024	Dr Kaufman has treated me before for a Bone Marrow Transplant. I respect his credentials and his knowledge based on his previous work with me.
One star One star One star One star One star	11/06/2024	This was a visit where it was critical that my caregiver and I fully understand the implications of the proposed treatment plan. Dr. Kaufman was very deliberate and candid in his explanations of the benefits and risks. All of our questions were answered and we were comfortable with the plan going forward.
One star One star One star One star One star	11/02/2024	All went well during the entireVisit.
One star One star One star One star One star	10/25/2024	Dr. Kaufman always seems to be prepared for each patient visit I have, and he takes the necessary time to answer all of my questions. Additionally, he seems to be genuinely concerned for my well-being and continued good health going forward. Since my life Is In his hands, it is extremely important that I can trust this man to make the right decisions for my continued good health in the years ahead.
One star One star One star One star Empty star	09/21/2024	Good
One star One star One star One star One star	09/21/2024	Dr. Kaufman is excellent
One star One star One star One star One star	09/11/2024	Dr Kaufman is excellent! I've been with him since 2013.
One star One star One star One star One star	08/26/2024	Doctor went over everything with me.
One star One star One star One star One star	08/23/2024	I have seen Dr Kaufman for 15 years. He is friendly, knowledgeable and very thorough.I look forward to seeing him every year. But I am also glad my cancer is in remission.
One star One star One star One star One star	08/18/2024	Dr. Kaufman is absolutely a wonderful person and physician. He is extremely smart and knowledgeable. He is kind and has excellent patient skills.
One star One star One star One star One star	08/07/2024	I truly appreciate the thoroughness of the medical explanations given!
One star One star One star One star One star	07/31/2024	Excellent professional conversation
One star One star One star One star One star	07/19/2024	I feel so fortunate to be in Dr Kaufman's care. He is the best of the best! He always listens to my concerns, and takes time to answer all of my questions. His follow up is outstanding! Any future visits or procedures needed are always set up right away. The care that I receive through Dr Kaufman's office is very good. I appreciate him so much!
One star One star One star One star One star	06/30/2024	The doctor was personable and caring
One star One star One star One star One star	06/08/2024	Dr. Kaufman was patient and answered all of my questions and concerns. He gave great insight to all of my issues
One star One star One star One star One star	06/02/2024	I always appreciate and am thankful for the time spent with me and that all of my questions and concerns are talked about with me by Dr. Kaufman